The Absolute Effect / Oncology Evidence
Prostate Cancer Trial Evidence
Clinical trial evidence for prostate cancer, organized around the decisions that matter: observation or treatment, postoperative radiotherapy, systemic intensification and management of metastatic hormone-sensitive disease.
Featured evidence
- ProtecT — long-term trade-offs between monitoring, surgery and radiotherapy for localized prostate cancer.
- CHAARTED — addition of docetaxel to androgen-deprivation therapy in metastatic hormone-sensitive disease.
- RTOG 0534 SPPORT — postoperative radiotherapy, androgen-deprivation therapy and pelvic nodal treatment.
- GETUG-AFU 16 — salvage radiotherapy with short-term androgen deprivation.
Absolute treatment effect
The key question is not only whether a treatment changes a hazard ratio or relative risk, but how many patients experience a clinically meaningful difference over a defined time horizon.